Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.
Research output: Contribution to journal › Article
This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Diabetes therapy : research, treatment and education of diabetes and related disorders|
|Publication status||Published - 2014|
No data available
Related research output
Aliasghar Ahmad Kiadaliri, 2014, Health Economics. 57 p.
Research output: Thesis › Doctoral Thesis (compilation)